2023
Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
Leong S, Ali S, Zengin Z, Meza L, Dizman N, Ebrahimi H, Govindarajan A, Castro D, Li X, Kim T, Melamed S, Onyshchenko M, Pal S, Chehrazi-Raffle A. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi). Journal Of Clinical Oncology 2023, 41: 613-613. DOI: 10.1200/jco.2023.41.6_suppl.613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaProgression-free survivalSafety-net healthcare systemComprehensive cancer centerShorter progression-free survivalHistory of nephrectomyTertiary care centerOverall survivalLatinx patientsMRCC patientsClinical outcomesCare centerHealthcare systemHope Comprehensive Cancer CenterPoor-risk diseaseTertiary oncology centerImmune checkpoint inhibitorsLos Angeles County DepartmentMedian overall survivalRisk classificationClear cell histologyFirst-line therapyNumber of comorbiditiesKaplan-Meier methodBody mass index
2022
Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).
Ali S, Leong S, Meza L, Dizman N, Zengin Z, Kim T, Pak Y, Onyshchenko M, Pal S, Chehrazi-Raffle A. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo). Journal Of Clinical Oncology 2022, 40: 4554-4554. DOI: 10.1200/jco.2022.40.16_suppl.4554.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaIpi/nivoProgression-free survivalTertiary care centerSafety-net healthcare systemCare centerHispanic/LatinxMultivariate Cox proportional hazards regressionShorter progression-free survivalCox proportional hazards regressionSafety-net hospital systemHope Comprehensive Cancer CenterFirst-line ipilimumabFirst-line therapyImmune checkpoint inhibitorsLos Angeles County DepartmentClear cell histologyNumber of comorbiditiesKaplan-Meier methodProportional hazards regressionComprehensive cancer centerHealthcare systemRenal cell carcinomaMultiple social determinantsReal-world analysisProlonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.Peer-Reviewed Original ResearchSystemic therapyNational Comprehensive Cancer Network guidelinesMetastatic renal cell carcinomaStereotactic body radiation therapyMedian total doseClear cell histologyFirst-line therapyFrequent side effectsLines of therapyPreponderance of patientsRetrospective data collectionBody radiation therapyRenal cell carcinomaEfficacy of radiotherapyMRCC patientsMedian doseCell histologyNew regimensSystemic treatmentClinicopathologic characteristicsRT toxicityClinical benefitNetwork guidelinesSame therapyCell carcinoma